Trials / Conditions / Refractory Ovarian Carcinoma

Refractory Ovarian Carcinoma

13 registered clinical trials studyying Refractory Ovarian Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer NCT06315491	Cybrexa Therapeutics	Phase 2
Recruiting	MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048	Mayo Clinic	Phase 1
Recruiting	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000	Northwestern University	Phase 2
Suspended	Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors NCT04840589	National Cancer Institute (NCI)	Phase 1
Completed	Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, NCT04753216	Northwestern University	Phase 2
Recruiting	ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer NCT04055649	Ira Winer	Phase 2
Terminated	AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, o NCT04019288	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatr NCT04213794	Mayo Clinic	EARLY_Phase 1
Completed	A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan NCT03907527	Precigen, Inc	Phase 1
Terminated	Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen i NCT03691376	Roswell Park Cancer Institute	Phase 1
Completed	TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors NCT03756818	M.D. Anderson Cancer Center	Phase 1
Completed	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, NCT03026062	M.D. Anderson Cancer Center	Phase 2